Resources Press News Resources Webinars Events April 24, 2025 Ajinomoto Co., Inc. to Sell* its Entire Equity Stake in Ajinomoto Althea, a US-based Aseptic Fill/Finish CDMO (*Completed on May 1, 2025) Read more March 20, 2025 Ajinomoto Bio-Pharma Services Awarded CDMO Leadership Awards Read more November 29, 2024 Notice of Phone Outage Due to Power Interruption Read more October 7, 2024 Notice of Discontinuation of certain Products and Services Read more September 5, 2024 Leading Global CDMO Ajinomoto Bio-Pharma Services Joins CMAC as New Translation to Industry Collaborator Read more July 4, 2024 Regarding the problem with the inquiry form; resolved on July 4th. Read more June 12, 2024 Ajinomoto Bio-Pharma Services Announces the Approval of the 32nd Drug Product at their San Diego Sterile Fill Finish Site Read more March 12, 2024 Ajinomoto Bio-Pharma Services Garners Six ‘CDMO Leadership Awards,’ Further Establishing Its Industry Excellence Read more December 27, 2023 Notice Regarding Joint Research Agreement with RIBOMIC Inc. Read more July 21, 2023 Notice Regarding the Display of Consumption Tax Under Japan’s Invoice System GeneDesign, Inc. – Osaka SiteRead more May 18, 2023 Ajinomoto Bio-Pharma Services Announces Leadership Changes at US Facility Read more April 19, 2023 Ajinomoto Bio-Pharma Services Receives FDA Approval for High Potency Fill Line Read more Loading…Load More July 31, 2026 CDMOs Forge Links to Next-Gen Antibody Conjugates July 31, 2026 Manufacturing Materials for Clinical Trials – An Interview July 31, 2026 Speeding Development and Manufacturing of Materials for Clinical Trials – An Interview July 31, 2026 Emphasizing Sustainability in Contract Manufacturing – An Interview July 31, 2026 Panel Discussion – Part III: CDMO Strategy in a COVID-19 World July 31, 2026 Application of Native Ion Exchange Mass Spectrometry to Intact and Subunit Analysis of Site-Specific Antibody–Drug Conjugates Produced by AJICAP First Generation Technology July 31, 2026 Interview – A CDMO for the Future: Adapting Services for Evolving Needs July 31, 2026 Good Manufacturing Practice Strategy for Antibody–Drug Conjugate Synthesis Using Site-Specific Chemical Conjugation: First-Generation AJICAP July 31, 2026 Contract Pharma’s 20th Anniversary Retrospective Loading…Load More November 30, 2023 Optimizing Plasmid Production Strategies & Partnerships Read more November 30, 2023 Q&A: Championing Change: Optimizing Plasmid Production Strategies Read more August 30, 2023 How To Select The Ideal HPAPI Manufacturing Partner Read more August 30, 2023 Q&A: Implement A Risk-Based Approach To Safely Manufacture HPAPIs Read more August 9, 2023 Prioritize Safety and Mitigate Risk in HPAPI Manufacturing Read more June 2, 2023 To GMP Or Not To GMP? That Is The (Plasmid) Question Read more March 20, 2023 AJICAP Second Generation: Improved Chemical Site-Specific Conjugation Technology for Antibody–Drug Conjugate Production Read more March 16, 2023 Mark Cassidy – Our Mission and Vision We are proud to produce more than 1 billion doses of life-saving medicine every year. Learn more about our mission…Read more March 14, 2023 Q&A: Innovative Solutions to Reduce the Environmental Footprint of Oligonucleotides Read more February 22, 2023 Identifying Sustainable Pathways Toward Oligonucleotide Therapeutics Read more January 11, 2023 How to Adapt Efficiently to a New Era of Supply Chain Manufacturing Read more December 1, 2022 Q&A: Managing Outsourcing For Complex Formulations Read more Loading…Load More November 18, 2025 Webinar – Engineering the Future of API Manufacturing: A Scientific Approach to Continuous Flow July 3, 2024 Webinar – You Had Me At Flow: The Shift From Batch To Continuous March 13, 2024 Webinar – Breaking Bad Manufacturing Habits: Strategies For Sustainable API Production November 28, 2023 Plasmid Production: The Benefits of Working with an Experienced CDMO May 9, 2023 Strategies for Scaling HPAPI Production Webinar December 5, 2022 Sustainable Approaches to Oligonucleotide Manufacturing January 10, 2022 The Paradigm Shift to Continuous Flow Processes: A Holistic View May 12, 2021 Plasmid Manufacturing for Gene Therapies: An Outsourcing Partnership Duration January 28, 2021 Oligonucleotide Therapeutics: Bridging from Research to Commercial Loading…Load More August 4, 2026 Oligonucleotide-Based Therapeutics Conference August 4, 2026 The Bioprocessing Summit 2026